Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.56 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2260204 | 0.98 | PARP1 (0.55) | PARP1PARP10PARP11NOTUMHTR5A | |
| SCHEMBL30826409 | 0.89 | NUDT1 (0.47) | PARP1PARP10PARP11HTR5AHTR1D | |
| SCHEMBL5757236 | 0.89 | NUDT1 (0.47) | PARP1PARP10PARP11HTR5AHTR1D | |
| SCHEMBL6221804 | 0.88 | PARP1 (0.44) | PARP1PARP10PARP11HTR5AHTR1D | |
| SCHEMBL31170775 | 0.88 | PARP1 (0.44) | PARP1PARP10PARP11HTR5AHTR1D | |
| SCHEMBL10923036 | 0.83 | PARP10 (0.53) | PARP1PARP10PARP11NOTUMNUDT1 | |
| SCHEMBL30916119 | 0.77 | NOTUM (0.47) | PARP1PARP10PARP11NOTUMBRD4 | |
| SCHEMBL20539302 | 0.77 | NOTUM (0.47) | PARP1PARP10PARP11NOTUMBRD4 | |
| SCHEMBL20777511 | 0.77 | HTR5A (0.52) | PARP1PARP10PARP11NOTUMHTR5A | |
| SCHEMBL22326634 | 0.75 | NOTUM (0.41) | PARP1PARP10PARP11NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722187-A1 | BUILDING BLOCK FOR TRIFLUOROALKYLATION AND TRIFLUOROALKYLATION METHOD USING SAME | Seoul National University Hospital (KR) | 2026-04-08 | — | — | EP | claimed |
| WO-2024242479-A1 | BUILDING BLOCK FOR TRIFLUOROALKYLATION AND TRIFLUOROALKYLATION METHOD USING SAME | 서울대학교병원 | 2024-11-28 | — | — | WO | claimed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4722187-A1 | BUILDING BLOCK FOR TRIFLUOROALKYLATION AND TRIFLUOROALKYLATION METHOD USING SAME | Seoul National University Hospital (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024242479-A1 | BUILDING BLOCK FOR TRIFLUOROALKYLATION AND TRIFLUOROALKYLATION METHOD USING SAME | 서울대학교병원 | 2024-11-28 | — | — | WO | disclosed |
| CN-112312899-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-1138042-A | Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | BRISTOL MYERS SQUIBB CO (US) | 1996-12-18 | — | — | CN | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0729958-A2 | Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and pyrimidinyl-piperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5521188-A | Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
| CN-1112561-A | Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-11-29 | — | — | CN | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| EP-0645385-A1 | Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | Bristol-Myers Squibb Company (US) | 1995-03-29 | — | — | EP | disclosed |
| US-5047539-A | Ultraviolet radiation stabilizers | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0399278-A2 | Heterocyclic amidine derivatives | BASF Aktiengesellschaft (DE) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | PARP1 474/4885PARP10 3986/4885PARP11 842/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | PARP1 307/4885PARP10 705/4885PARP11 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.